Clinical Trial Details
| Trial ID: | L2482 |
| Source ID: | NCT04304560 |
| Associated Drug: | Dapagliflozin 10 Mg |
| Title: | Value of SGLT2 Inhibitor (Dapagliflozin) as an Added Therapy in Diabetic Patients With Heart Failure With Reduced Ejection Fraction; Randomized Controlled Clinical Trial |
| Acronym: | |
| Status: | UNKNOWN |
| Study Results: | NO |
| Results: | |
| Conditions: | Heart Failure With Reduced Ejection Fraction (HFrEF)|Diabete Type 2|Cardiomyopathies |
| Interventions: | DRUG: Dapagliflozin 10 MG|DRUG: Placebo oral tablet |
| Outcome Measures: | Primary: LV dimensions, Echocardiography, 3 Months|Systolic function, Echocardiography, 3 Months|Diastolic Function, Echocardiography, 3 Months | Secondary: HbA1c, Glycemic control, 3 Months|Myeloperoxidase (MPO), Oxidative stress marker, 3 Months|N-terminal pro b-type Natriuretic Peptide (proBNP-N), Fibrosis marker, 3 Months|Galectin -3, Fibrosis marker, 3 Months |
| Sponsor/Collaborators: | Sponsor: Damanhour University | Collaborators: Menoufia University |
| Gender: | ALL |
| Age: | ADULT, OLDER_ADULT |
| Phases: | PHASE2 |
| Enrollment: | 60 |
| Study Type: | INTERVENTIONAL |
| Study Designs: | Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, CARE_PROVIDER)|Primary Purpose: TREATMENT |
| Start Date: | 2020-03 |
| Completion Date: | 2021-04 |
| Results First Posted: | |
| Last Update Posted: | 2020-03-11 |
| Locations: | |
| URL: | https://clinicaltrials.gov/show/NCT04304560 |
